Striving to Achieve Improved Outcomes:
An Integrated Approach to HCV Treatment

View Webcast (requires free Flash plug-in)

Download Tx Reporter

Tx Reporter Posttest & Evaluation (Please read the Tx Reporter
before taking the on-line Posttest & Evaluation.)

Dear Colleague:

One of the greatest challenges for hepatologists is to manage the sometimes troublesome and treatment-limiting side effects of the more effective antiviral therapies that have become available for hepatitis C in the past decade. Disciplines outside of hepatology have forged ahead in their scientific understanding of hematologic and neuropsychiatric side effects associated with cytokine therapies and have a great deal of exciting new information to share with us. If you missed Striving to Achieve Improved Outcomes: An Integrated Approach to HCV Treatment, the CME satellite symposium that took place during the Liver Meeting 2004, here's another opportunity to view this exciting symposium via our free CME webcast. You can also download the Tx Reporter newsletter, which covers all of the in-depth information and expertise offered by experts in hepatology/liver disease, hematology/oncology, and psychiatry.

Oncologist Ursula A. Matulonis, MD, illuminates just how detrimental anemia is to quality of life. She also elucidates newly recognized benefits of growth factors, including enhancement of quality of life and potential for neuroprotection. Andrew H. Miller, MD, explores investigations in psychiatry that have uncovered a relationship between behavioral symptoms and anti-HCV treatment outcome, and describes pathophysiologically different types of depression syndromes associated with interferon that may warrant more complex approaches to treatment. Hepatologist Zobair M. Younossi, MD, MPH, shows you new data in the hepatitis C population indicating improved quality of life through treatment of anemia.

This exciting program incorporates shared experiences across specialties, enhances physician education on hepatitis C, and ultimately improves patient care and optimizes treatment outcomes.

Sincerely,

top

Development Faculty

CHAIR

The CME webcast and CME Tx Reporter newsletter are designed for gastroenterologists and other physicians who treat patients with HCV infection.

Activity Goal

The goal of these activities is to apply lessons derived from treatment issues in other disease states to hepatitis C with the intent of benefiting patients with HCV infection.

Learning Objectives

After participating in these activities, the physician should be able to:

• Anticipate hematologic and neuropsychiatric side effects and diminished quality of life in HCV-infected patients on combination antiviral therapy.
• Relate treatment-associated side effects and diminished quality of life to reduced treatment adherence and to suboptimal patient outcomes.
• Translate clinical experiences from the fields of oncology and psychiatry into models for side effect prevention and management in patients with HCV infection.
• Formulate strategies for managing hematologic and neuropsychiatric disorders associated with HCV therapy to achieve optimal outcomes in patients on antiviral therapy.

top

Contract for Mutual Responsibility in CME/CE

CME Information

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this CME webcast for a maximum of 1.5 Category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Projects In Knowledge designates the Tx Reporter newsletter activity for a maximum of 0.5 Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

These activities are planned and implemented as independent CME activities in accordance with the ACCME Essential Areas and Policies.

Disclosure Information

The Disclosure Policy of Projects In Knowledge requires that faculty participating in a CME activity disclose to the audience: any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation; any relationship with the commercial supporter of this activity; if discussion includes 1) therapies that are unapproved for use or are investigational; 2) ongoing research; or 3) preliminary data. Faculty will disclose such discussion.

For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Ursula A. Matulonis, MD, is on the speakers bureau of Amgen Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, and Ortho Biotech Products, LP. Dr. Matulonis has disclosed that she will reference the unlabeled/unapproved use of epoetin.

John G. McHutchison, MD, FRACP, has received grant/research support from Akros Pharma Inc, Amgen Inc, Bayer Pharmaceuticals, BioMedicines, Bristol-Myers Squibb Company, Cytel Corporation, Fujisawa Healthcare, Inc, GenProbe, Gilead Sciences, Inc, Idun Pharmaceuticals, Isis Pharmaceuticals, Inc, Ortho Diagnostic Systems, Inc, Prometheus Laboratories, Ribozyme Pharmaceuticals, Inc, Roche Pharmaceuticals, Schering-Plough Corporation, SciClone Pharmaceuticals, Triangle Pharmaceuticals Inc, and Vertex Pharmaceuticals, Inc; is a consultant for Amgen Inc, Anadys Pharmaceuticals, Inc, Centocor, Inc, GlaxoSmithKline, InterMune Inc, Isis Pharmaceuticals, Inc, National Genetics Institute Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Prometheus Laboratories, Ribozyme Pharmaceuticals, Inc, and Schering-Plough Corporation; and is on the speakers bureau of InterMune Inc, Roche Pharmaceuticals, and Schering-Plough Corporation. Dr. McHutchison has disclosed that he will reference the unlabeled/unapproved use of erythropoietins.

Andrew H. Miller, MD, has received grant/research support from GlaxoSmithKline, Janssen Pharmaceutica Products, LP, and Schering-Plough Corporation. Dr. Miller has disclosed that he will reference the unlabeled/unapproved use of dopamine reuptake inhibitors/dopamine agonists and paroxetine.

The opinions expressed in these activities are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

These CME activities are provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient.

Peer Review process provided by the University of Pennsylvania School of Medicine Office of CME. To find out more information click here.

Webcast Release Date:
November 22, 2004.

Webcast Termination Date:
November 22, 2005.

Estimated time for completion of this webcast: 1.5 hours

Available Now!
4-page Newsletter

Tx Reporter Release Date:
February 18, 2005.

Tx Reporter Termination Date:
February 18, 2006.

Estimated time for completion of this newsletter: 0.5 hour

These independent CME activities are supported by an educational grant from Amgen Inc.

The CME webcast and CME Tx Reporter newsletter are designed for gastroenterologists and other physicians who treat patients with HCV infection.

Activity Goal

The goal of these activities is to apply lessons derived from treatment issues in other disease states to hepatitis C with the intent of benefiting patients with HCV infection.